The landmark observation of programmed death 1 (PD-1) blockade leading to remarkable clinical responses in mismatch-repair (MMR)-deficient colorectal and endometrial cancers [1] has heightened the need to identify these types of cancer. According to the National Comprehensive Cancer Network (NCCN) guidelines, screening for MMR-deficiency in all endometrial cancers (EC) regardless of age has become the standard at many major medical centers to identify individuals at risk for Lynch Syndrome (LS) [2]. Methods for screening for LS utilizing immunohistochemistry (IHC: MLH1, PMS2, MSH2, and MSH6) or microsatellite instability (MSI) analysis have been extensively evaluated [3, 4]. Debate has remained as to the most appropriate method to utilize in population-based screening and has focused mostly on identification of LS...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.